🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "major milestone" in the fight against drug-resistant strains of the infection, according to health experts.

An International Challenge

The sexually transmitted infection are escalating around the world, with figures suggesting more than 82 million infections each year. Especially elevated rates are seen in the African continent and nations within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune development in the face of rising global incidence, the spread of superbugs and the extremely scarce available drugs currently available.”

Public health authorities are increasingly worried about the surge in drug-resistant strains. The World Health Organization has designated it as a "critical concern". Recent surveillance showed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Receive Authorization

One new antibiotic, alternatively called a brand name, was approved by the US FDA in mid-December for combating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Scientists believe that targeted use of this new drug will help delay the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GSK, was also approved in close succession. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin was the result of a unique collaborative effort for drug creation. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to bring it to fruition.

“This approval marks a major breakthrough in the treatment of superbug gonorrhoea, which previously has been evolving faster than medical innovation.”

Clinical Trial Results and Worldwide Availability

According to data released by a prominent scientific publication, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This establishes an equal footing with the typical regimen, which combines a dual-drug approach. The study involved hundreds of volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the rights to make available and distribute the drug in numerous developing nations.

Medical professionals treating patients have expressed positive views. Access to a one-pill regimen such as this is seen as a "critical tool" for managing the epidemic. This is viewed as essential to lessen the impact of the illness for people and to halt the transmission of untreatable gonorrhoea globally.